ATEM Capital Fund LP
VC Fund
New York, United States
ATEM Capital Fund LP is a VC fund in New York focused on Health Care and Medical. ATEM Capital (atemcap.com) is a NY-based Life Sciences investment fund that invests in breakthrough BioPharma / MedTech / Digital Health. Our prioritized therapeutic areas are platform technologies to cure oncology, autoimmune, cardiovascular, neurology diseases, and infections. In the last years, our team had over ten successfulco-investments with the leading venture firms of the US and Europe: OrbiMed, Domain Associates, Canaan, ProQuest, LSP, Aisling Capital, MPM, Alta Partners, Frazier, Sofinnova, KPCB, as well as with the corporate venture firms: Pfizer, Roche, J&JDC, Novo, etc. Prioritized therapeutic areas are oncology, autoimmune diseases, rare diseases, and neurology. Our team members have extensive hands-on experience in product launches (over 40 products in the US and Europe), investments management (over $30 billion overall investment/liquidity), and exits of venture-backed companies.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries ATEM Capital Fund LP invests in
Stages ATEM Capital Fund LP invests in
Countries ATEM Capital Fund LP invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Allan Gobbs
|
|||
4 more contacts available
Investment Focus
Industry
- Health Care 5 (71%)
- Medical 3 (43%)
- Life Science 3 (43%)
- Biotechnology 3 (43%)
- Hospital 2 (29%)
Stage
- Seed 3 (43%)
- Series B 3 (43%)
- Series A 1 (14%)
Country
- United States 6 (86%)
- France 1 (14%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Allan Gobbs
CEO, Managing Partner
|
CEO, Managing Partner | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
PGxAI
|
Category-defining revenue generating AI-powered TechBio platform. PGxAI has built a proprietary first-in-class GenAI pharmacogenetics (PGx) model, leveraging trusted clinical guidelines and FDA/EMA recommendations, to predict individual responses to substances using multi-omics data. We solve drug selection and dosage optimization challengeswith unparalleled accuracy and reproducibility. Released in Jul’24, Sirius, PGxAI's first AI model with 300K parameters, delivers 5X the drug-gene coverage of top competitors. Vega, released in Dec’24 with 10B parameters, achieves 70X coverage, which is unattainable without advanced AI. | $1.5M / Seed / Dec 24, 2024 | |
YCare
|
YCare is the leading AI-powered Hospital-At-Home platform, in partnership with InterSystems, Dell Technologies, and NTT. We provide a turn-key solution for providers to boost their hospital-at-home strategy and deliver efficient, comprehensive outpatient care.For Health Care Providers. YCare empowers health systems to bring care into the home,where patients feel safest and most comfortable. Implementing a Hospital-At-Home strategy is not just financially beneficial—it's essential to significantly enhance health outcomes and patient satisfaction. Our platform supports a full array of Medicare-reimbursed services, including remote patient monitoring, chronic care management, and telehealth, and features seamless EHR integration, real-time insights into personnel activities, and sophisticated billing and revenue management tools.For Health Care Practitioners. We equip physicians with cutting-edge, AI-enhanced Hospital-At-Home solutions for precise, real-time patient management. Our platform supports over 250 devices and is equipped to integrate any digital health tool or device you use, covering all Medicare-reimbursed services and more.For Patients And Caregivers. We equip family caregivers and nurses with cutting-edge AI mobile solutions for comprehensive support and real-time patient monitoring. YCare enables care teams to respond instantly to patient issues, coordinating across all caregivers. Our platform boosts caregiving with up to six-way communication, seamless EHR integration, and intuitive mobile apps for a comprehensive health overview. YCare's AI Nurse avatar personalizes care, continuously offers health suggestions, and keeps patients actively engaged, promptly escalating any issues to caregivers and healthcare providers. | Seed / Oct 01, 2024 | |
PGxCare
|
PGxCare offers an AI capabilities, enabling analysis of pharmacogenetic data ensuring accurate results tailored to individual needs. | $1.5M / Seed / Mar 19, 2024 | |
Walden Biosciences
|
Walden Biosciences is a biotechnology company focused on transforming the treatment of kidney disease. Founded by world-renowned experts in renal disease, Walden is applying its unique, systems-based approach to address the intersection between the pathology and biology of kidney disease. | Series B / Oct 01, 2023 | |
Triumvira Immunologics
|
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cellreceptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer. | $45M / Series A / Mar 17, 2022 | |
Amolyt Pharma
|
Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. | $80M / Series B / Sep 16, 2021 | |
Iridia
|
Iridia is a nanotechnology company that specializes in biochemistry, molecular biology, and DNA. develop the world’s first commercially-attractive, DNA-based data storage solution. It combines DNA polymer synthesis technology, electronic nano-switches, and semiconductor fabrication technologies, Iridia is developing a highly-parallel format toenable an array of nanomodules with the potential to store data at exceptionally high density.The company was founded in 2016 and headquartered in California, United States. | $24M / Series B / Mar 16, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does ATEM Capital Fund LP invest in?
ATEM Capital Fund LP invests primarily in Health Care, Medical and Life Science startups, most often at Seed and Series B stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact ATEM Capital Fund LP?
Public channels for ATEM Capital Fund LP include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at ATEM Capital Fund LP?
The team at ATEM Capital Fund LP includes Allan Gobbs (CEO, Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
